Log In
BCIQ
Print this Print this
 

APG101, CAN-008 (formerly Apocept)

  Manage Alerts
Collapse Summary General Information
Company Apogenix AG
DescriptionFusion protein consisting of the extracellular domain of CD95 fused to the Fc region of human IgG that inhibits CD95-CD95 ligand interactions
Molecular Target Fas receptor (CD95)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/28/2015

Undisclosed

Undisclosed

Undisclosed

07/15/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today